DEA Fights Hemp Firm's Bid to Challenge HHC Ban in Court

August 15, 2026

Photo by Dad Grass via Pexels.

On August 11, 2026, DEA lawyers filed a brief with the Fourth Circuit Court of Appeals that does something federal agencies love to do when they'd rather not defend a rule on its face: argue the other side has no right to be in court at all. The target is Bluestar Operations, a hemp company that sued to overturn DEA's decision to give hexahydrocannabinol, better known as HHC, its own dedicated drug code under the Controlled Substances Act. DEA's brief argues Bluestar lacks standing to bring the challenge in the first place, and then, almost as an afterthought, adds that Bluestar would lose on the merits anyway even if a judge disagreed.

That double-barreled approach tells you something about how DEA wants this fight to end -- decisively, and without ever really having to defend the substance of its own rulemaking. This isn't an isolated skirmish. It's the latest round in a much larger argument over whether hemp-derived synthetic cannabinoids like HHC survive the legal carve-out Congress created in the 2018 Farm Bill, or whether they were always illegal drugs wearing a hemp costume. Two companies, Bluestar and a separate business called IHC Investments, are now pushing near-identical arguments in two different appeals courts -- the Fourth Circuit and the Ninth Circuit -- and how those cases land could determine whether an entire category of products stays on shelves or disappears from the market almost overnight.

What DEA Actually Argued This Week

Photo by advogadoaguilar via Pixabay.

DEA's brief to the Fourth Circuit builds its case in two layers, and it's worth understanding both because they lead to very different outcomes if a court buys them. The first layer is procedural: DEA says Bluestar simply doesn't have standing to challenge the rule, meaning the company hasn't shown the kind of direct, concrete injury that gives it the right to sue in federal court over this particular agency action. If the Fourth Circuit agrees, the case gets tossed without judges ever weighing in on whether HHC is actually legal -- a tidy outcome for an agency that would rather not create binding precedent on the merits.

The second layer is where DEA shows its actual legal theory, in case the standing argument fails. The agency's position is that HHC has effectively been a Schedule I controlled substance for years already, not because of any new rule, but because of its chemical structure. DEA has long argued that HHC is close enough to THC in molecular terms to fall under existing Controlled Substances Act provisions covering THC isomers and analogues -- meaning the May 2026 rule change didn't outlaw anything new, it just gave an already-illegal substance its own bureaucratic drug code for tracking and enforcement purposes.

That framing matters because it lets DEA argue the hemp exemption written into the 2018 Farm Bill never applied to HHC to begin with. DEA reads that exemption narrowly, as protection for cannabinoids that occur naturally in the cannabis plant -- CBD, for instance -- not for compounds like HHC that are typically produced by chemically converting CBD in a lab. Under that reading, HHC was never truly hemp-derived in the sense Congress intended to protect, no matter how it's marketed or where the starting material came from.

The Rule at the Center of the Fight

Photo by Elsa Olofsson via Unsplash.

The rule that started all this is formally titled Specific Listing for Hexahydrocannabinol, and DEA published it on May 4, 2026. On paper, it's a narrow administrative move: it assigns HHC its own unique drug code under Schedule I, separating it out from the general catch-all listings that previously covered THC analogues. DEA has been consistent in describing this as a housekeeping change, something that doesn't alter HHC's legal status because, in the agency's view, HHC was already controlled under existing law before the rule ever existed.

Hemp companies see it very differently, and it's not hard to understand why. A dedicated drug code isn't just paperwork -- it hands DEA agents, prosecutors, and customs officials a clean, unambiguous label to act on. Before the rule, HHC sat in a gray zone that let retailers, distributors, and manufacturers operate with at least some plausible legal cover, and that ambiguity is precisely what allowed HHC products to become a fixture in smoke shops and online stores over the past several years. Once a compound has its own Schedule I code, that argument gets a lot harder to make, and enforcement gets a lot easier to justify.

The practical stakes became clear back in June, when the Fourth Circuit denied Bluestar's request to stay the rule while litigation played out. That denial meant the drug code took effect and has remained in effect throughout the appeal, giving DEA the exact enforcement tool it wanted well before any court has ruled on whether the underlying legal theory holds up. Businesses have been operating under that cloud for months now, with no guarantee the rule gets undone even if Bluestar eventually wins.

Two Companies, Two Circuit Courts

Photo by Daniel_B_photos via Pixabay.

Bluestar isn't fighting alone, even if the two cases aren't formally joined. A separate company, IHC Investments Inc., filed its own petition challenging the same HHC drug code, and that case is now sitting before the Ninth Circuit rather than the Fourth. Running parallel challenges in two different circuits is a common strategy when a company wants multiple shots at a favorable outcome, but it also means two panels of judges, with no obligation to agree with each other, will be interpreting the same statute and the same rule.

Bluestar's strategy in the Fourth Circuit leans heavily on a prior ruling from that same court involving THC-O-acetate, another synthetic hemp-derived cannabinoid, where judges found the compound fell within the Farm Bill's protections despite DEA's objections. If that precedent extends cleanly to HHC, Bluestar has a real path to victory -- which is likely part of why DEA's brief spends so much energy trying to get the case dismissed on standing grounds before that comparison ever gets a full hearing.

Over on the IHC Investments side, attorney David Sergi has been blunt about what's at stake, arguing the reclassification directly contradicts the language Congress wrote into the 2018 Farm Bill. Sergi has also pointed to the human cost playing out while the legal theory gets sorted out in court: businesses losing contracts overnight, banks cutting off accounts tied to HHC sales, and warehouses full of inventory that could legally have to be destroyed depending on how these cases resolve. A split between the Fourth and Ninth Circuits wouldn't just be an academic curiosity -- it's exactly the kind of disagreement that tends to land a case in front of the Supreme Court, or push Congress to finally settle the question through legislation instead of leaving it to competing appellate panels.

Congress Is Quietly Buying Time

Photo by Ivan Dražić via Pexels.

While the courts sort through standing arguments and molecular chemistry, Congress has been working a quieter angle that could end up mattering more than either circuit court ruling. The Senate approved a provision attached to a funding bill that delays the effective date of a broader ban on hemp-derived cannabinoid products, pushing that deadline to December 11, 2026. The White House has backed the delay, giving it more momentum than a typical rider usually carries.

As of this reporting, though, that delay hasn't cleared the House and hasn't been signed into law -- it's a pending provision, not a settled fact, and hemp businesses would be wise not to treat it as guaranteed. The gap between Senate approval and final enactment is exactly where these things tend to stall or get renegotiated, especially on a topic as politically split as hemp policy.

Industry advocates are treating the delay, tentative as it is, as a rare opening. Rather than fighting purely defensive battles in court, groups representing hemp retailers and manufacturers are using this window to push Congress toward an actual regulatory framework for cannabinoids like HHC -- testing standards, potency limits, age restrictions -- instead of the current pattern of blanket bans followed by scattered litigation. It's a fundamentally different approach than what's happening in the Fourth and Ninth Circuits, running on its own legislative calendar and its own political logic.

The two tracks aren't unrelated, though. A meaningful congressional fix, even a partial one, could moot large chunks of the ongoing court fights by settling the underlying legal question that DEA and the hemp industry are currently asking judges to answer for them. That's part of why December 11 matters as much as any court date on the Fourth Circuit's calendar.

The part of DEA's brief worth watching closest isn't the HHC chemistry argument -- it's the standing argument. If the Fourth Circuit accepts DEA's position that Bluestar can't even bring this challenge, it sets a template other courts could follow, making it substantially harder for any hemp company to contest a DEA scheduling decision in the future. That outcome would ripple well past HHC, effectively giving the agency a procedural shield against judicial review of how it classifies hemp-derived compounds generally.

None of this looks like it gets resolved cleanly through the courts anytime soon. Between a possible circuit split, an agency arguing procedural dismissal rather than defending its rule on the merits, and a legal theory that hinges on reading Farm Bill language DEA itself gets to interpret, litigation could drag on for years without producing a clear national answer. The date that actually matters here is December 11 -- if the House passes the delay and it gets signed into law, it buys the hemp industry real time to push for a legislative framework rather than leaving HHC's fate to whichever circuit rules first.

For anyone currently selling HHC, delta-8, or similar synthetic cannabinoids, the sensible read of all this is caution, not comfort. Nothing here amounts to a green light, and the legal ground under these products remains genuinely unsettled at the federal level. It's also worth remembering that federal litigation is only half the picture -- a number of states have already banned HHC outright regardless of what DEA or any circuit court eventually decides, so checking state-specific rules matters just as much as watching Washington.